Asiantuntijamme ovat kirjoittaneet, osallistuneet ja antaneet näkemystä satoihin julkaisuihin.
Puolitaival A, Savola M, Tuomainen P, Asseburg C, Lundström T, Soini E. Advantages in Management and Remote Monitoring of Intravenous Therapy: Exploratory Survey and Economic Evaluation of Gravity-Based Infusions in Finland. Adv Ther 2022.
Mälkönen T, Nuutinen P, Hallinen T, Soini E, et al. Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis. Acta Derm Venereol 2022; 102: adv00631.
Tew M, Willis M, Asseburg C, et al. Exploring structural uncertainty and impact of health state utility values on lifetime outcomes in diabetes economic simulation models: Findings from the Ninth Mount Hood Diabetes Quality-of-Life Challenge. Med Decis Making 2021.
Hallinen T, Soini E, Asseburg C, et al. Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation. Clinocoecon Outcomes Res 2021;13:745–755.
Sipponen T, af Björkesten CG, Hallinen T, Ilus T, Soini E, et al. A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn’s disease patients in Finland. Scand J Gastroenterol 2021.
Af Björkesten CG, Ilus T, Hallinen T, Soini E, et al. Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohort. Eur J Gastroenterol Hepatol 2020 (online ahead of print).
Väätäinen S. Diabetesriski, suurentunut paastoglukoosi ja heikentynyt glukoosinsieto ovat yhteydessä heikentyneeseen terveyteen liittyvään elämänlaatuun. Erikoislääkäri 2020;30(2):56-8.
Väätäinen S. Health Utility along the diabetes continuum, examination of utility values in impaired glucose metabolism using pre-scored multi-attribute utility instruments. Doctoral dissertation. Publications of the University of Eastern Finland. Dissertations in Health Sciences, no 555. Kuopio: University of Eastern Finland, 2020.
Kakkostyypin diabeteksen tutkija myöntää: "Terveiden elämäntapojen noudattaminen on haaste itsellenikin." Mediuutiset 2020;(18):13. Medipersoona: Väätäinen S.
Psoriaasi ja nivelpsoriaasi. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecimin ja Suomen Ihotautilääkäriyhdistyksen asettama työryhmä. Helsinki: Suomalainen Lääkäriseura Duodecim, 2020 (viitattu 4.8.2020). Asiantuntija: Soini E.
af Björkesten CG, Ilus T, Hallinen T, Soini E, et al. Real-life dosing patterns and concomitant drug use among ustekinumab-treated patients with Crohn’s disease. Digital Oral Poster (DOP) 26. Journal of Crohn's and Colitis 2020;14 (Issue Supplement 1):S066.
af Björkesten CG, Ilus T, Hallinen T, Soini E, et al. Objectively assessed disease activity during ustekinumab treatment in a nationwide real-life Crohn’s disease cohort. Journal of Crohn's and Colitis 2020;14 (Issue Supplement 1):S434–S435.
Väätäinen S, Soini E, et al. Alemtuzumab is a budget-saving alternative to fingolimod and natalizumab in the treatment of highly active relapsing-remitting multiple sclerosis. Dosis 2020;36(1):36-59.
Mankinen P, Lundström T, Soini E, et al. Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis. Adv Ther 2020;37 (2): 800-18.
Väätäinen S, Soini E, et al. Economic Value of Adjunctive Brivaracetam Treatment Strategy for Focal Onset Seizures in Finland. Adv Ther 2020; 37: 477-500.
Heiskanen J, Hartikainen J, Martikainen J, et al. Purchases of medical therapy recommended for coronary artery disease before and after elective revascularisation. Eur J Clin Pharmacol. 2020;76(1):81-88.
Väätäinen S, Soini E, et al. Cost-benefit predictions of the Virtual Hospital 2.0 digitalized secondary care path for women with endometriosis in Turku area and in Finland. eHealth2019 – International Conference 2019 & The 24th Finnish National Conference on Telemedicine and eHealth “Data-Driven Health”. Kuopio, Apr 2-3, 2019.
ISPOR Europe 2019 Conference Award Winner. PIH18: Predicted cost and capacity benefits of the digitalized secondary care path for women with endometriosis @ Virtual Hospital 2.0. Presenting Author: Erkki Soini, ESiOR Oy, Kuopio, 15, Finland.
Soini E, Väätäinen S. Kansainvälisten kustannusvaikuttavuustulosten siirrettävyys Suomeen: Rivaroksabaani ja varfariini eteisvärinän hoidossa. Best Practice Nordic - Diabetes ja sydänsairaudet 2019;7(27):12-15.
Kohti terveyttä edistävää Suomea 2030. StopDia – investointilaskurin tulosraportti. Sovellusversio 1.0.
StopDia-investointilaskuri tyypin 2 diabeteksen ehkäisyn terveystaloudellisten vaikutusten arviointiin. ESiOR Oy; application: Aug 21, 2019.
Soini E, Virtanen O, Väätäinen S, et al. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland. Adv Ther 2020; 37:3348–69.
Soini E. Tietoaltaat: Data-analytiikan, tiedon tuotannon ja terveystaloustulosten hyödyntäjän aarreaitta? eHealth2019 – International Conference 2019 & The 24th Finnish National Conference on Telemedicine and eHealth “Data-Driven Health”. Kuopio, Apr 2, 2019.
Väätäinen S, Soini E, et al. Cost-benefit evaluation of digital HealthyWeightHub: Virtual Hospital 2.0. eHealth2019 – International Conference 2019 & The 24th Finnish National Conference on Telemedicine and eHealth “Data-Driven Health”. Kuopio, Apr 2-3, 2019.
Soini E, Väätäinen S, et al. Digitalized secondary care services for insulin-dependent diabetes patients – Predictive cost-benefit analysis of Virtual Hospital 2.0 digital care path. eHealth2019 – International Conference 2019 & The 24th Finnish National Conference on Telemedicine and eHealth “Data-Driven Health”. Kuopio, Apr 2-3, 2019.
Hallinen T, Soini E, et al. Child placement costs and cost drivers: Isaacus Kuopio data lake project. eHealth2019 – International Conference 2019 & The 24th Finnish National Conference on Telemedicine and eHealth “Data-Driven Health”. Kuopio, Apr 2-3, 2019.
Eberl A, Hallinen T, af Björkesten C-G, Heikkinen M, Hirsi E, Kellokumpu M, Koskinen I, Moilanen V, Nielsen C, Nuutinen H, Suhonen U-M, Utriainen K, Vihriälä I, Soini E, et al. Ustekinumab for Crohn’s disease: a nationwide real-life observational cohort study from Finland. Journal of Crohn's and Colitis 2019;13(Supplement 1): S415–S416.
Purmonen T, Puolakka K, Mishra D, Gunda P, Martikainen J. Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland. Clinicoecon Outcomes Res 2019;11:159-168.
Taipale J, Mikhailova A, Ojamo M, Nättinen J, Väätäinen S, et al. Low vision status and declining vision decrease Health-Related Quality of Life: Results from a nationwide 11-year follow-up study. Qual Life Res 2019;28(12):3225-36.
Eberl A, Hallinen T, Af Björkesten CG, Heikkinen M, Hirsi E, Kellokumpu M, Koskinen I, Moilanen V, Nielsen C, Nuutinen H, Suhonen UM, Utriainen K, Vihriälä I, Soini E, et al. Ustekinumab for Crohn’s disease: a nationwide real-life cohort study from Finland (FINUSTE). Scandinavian Journal of Gastroenterology 2019;54(6):718-25.